Medicine

Medicine & Life Sciences

1. Therapeutics 100%
2. Neoplasms 83%
3. Percutaneous Coronary Intervention 72%
4. Mortality 62%
5. Inflammatory Bowel Diseases 62%
6. Crohn Disease 54%
7. HIV 54%
8. Confidence Intervals 54%
9. Myocardial Infarction 54%
10. Genes 53%
11. Kidney 52%
12. Liver 50%
13. Heart Failure 50%
14. Atrial Fibrillation 49%
15. Orthomyxoviridae 49%
16. Coronavirus 49%
17. T-Lymphocytes 49%
18. Safety 48%
19. Hepatocellular Carcinoma 45%
20. Multiple Myeloma 44%
21. Transplants 44%
22. Population 43%
23. Meta-Analysis 42%
24. Proteins 42%
25. Ulcerative Colitis 41%
26. Survival 41%
27. Atherosclerosis 41%
28. Viruses 40%
29. Stents 40%
30. Cardiovascular Diseases 39%
31. Infections 39%
32. Coronary Artery Disease 39%
33. Fibrosis 39%
34. Hemorrhage 38%
35. Clinical Trials 37%
36. Pandemics 37%
37. Hepacivirus 36%
38. Thrombosis 35%
39. Inflammation 35%
40. Antibodies 34%
41. Biomarkers 33%
42. Incidence 33%
43. Odds Ratio 32%
44. Acute Coronary Syndrome 32%
45. Stroke 32%
46. Registries 31%
47. Chronic Renal Insufficiency 31%
48. Liver Transplantation 31%
49. Interferons 30%
50. HIV-1 30%
51. Wounds and Injuries 29%
52. Lung 29%
53. Spinal Cord Injuries 29%
54. Virus Diseases 29%
55. Pharmaceutical Preparations 29%
56. Serum 28%
57. Heart 27%
58. Placebos 27%
59. Guidelines 27%
60. Influenza A virus 27%
61. Randomized Controlled Trials 27%
62. Systematic Reviews 26%
63. Health 26%
64. Mutation 26%
65. Cohort Studies 26%
66. Atherosclerotic Plaques 26%
67. Coronary Vessels 25%
68. Breast Neoplasms 25%
69. Type 2 Diabetes Mellitus 25%
70. Blood Platelets 25%
71. Drug-Eluting Stents 25%
72. Hypertension 25%
73. Vaccines 25%
74. Prostatic Neoplasms 24%
75. Antiviral Agents 24%
76. Macrophages 24%
77. Physicians 24%
78. Blood Pressure 23%
79. Human Influenza 23%
80. Phenotype 23%
81. Lipids 23%
82. Equipment and Supplies 23%
83. Drug Therapy 23%
84. Blood Vessels 22%
85. Lung Neoplasms 22%
86. B-Lymphocytes 22%
87. Transplant Recipients 22%
88. Transcatheter Aortic Valve Replacement 22%
89. Hemagglutinins 22%
90. In Vitro Techniques 21%
91. Asthma 21%
92. Growth 21%
93. Apoptosis 21%
94. SARS Virus 20%
95. Hydroxymethylglutaryl-CoA Reductase Inhibitors 20%
96. Hepatitis C 20%
97. Gene Expression 20%
98. Primary Myelofibrosis 20%
99. Genome 20%
100. Obesity 20%